Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Vitiligo
ADR ID BADD_A04612
ADR Hierarchy
10      Immune system disorders
10.04      Autoimmune disorders
10.04.02      Skin autoimmune disorders NEC
10.04.02.004      Vitiligo
23      Skin and subcutaneous tissue disorders
23.05      Pigmentation disorders
23.05.02      Hypopigmentation disorders
23.05.02.004      Vitiligo
Description A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached. [MeSH]
MedDRA Code 10047642
MeSH ID D014820
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Vitiligo | Vitiligo vulgaris | Vitiligo aggravated
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00062Aldesleukin--
BADD_D00066Alendronic acid0.000303%
BADD_D00156Apremilast0.001737%
BADD_D00197Azelaic acid--
BADD_D00277Bisoprolol0.002683%
BADD_D00349Capecitabine0.000533%
BADD_D00680Dimethyl fumarate0.001834%
BADD_D00800Erlotinib0.000533%
BADD_D00898Finasteride0.000962%
BADD_D01136Imatinib0.000533%
BADD_D01142Imiquimod0.008110%
BADD_D01167Interferon alfa-2b--
BADD_D01285Levothyroxine0.000034%
BADD_D01431Methylphenidate0.000826%
BADD_D01581Nivolumab--
BADD_D01637Oxcarbazepine--
BADD_D01653Paclitaxel--
BADD_D01700Pembrolizumab--
BADD_D01803Porfimer sodium--
BADD_D01933Ribavirin0.018131%
BADD_D02010Sertraline0.000060%
BADD_D02093Sulfasalazine0.001382%
BADD_D02165Teriflunomide0.001737%
BADD_D02236Tofacitinib0.004632%
BADD_D02464Fingolimod0.001158%
The 1th Page    1    Total 1 Pages